Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 262

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 262
---
2. The amount of DiamiR’s future net losses will depend, in
part, on the rate of future growth of its expenses and DiamiR’s ability to generate revenues. If DiamiR is unable to develop and
commercialize CogniMIR or any other product candidates that it may seek to develop, either alone or with collaborators,
or if revenues from any product candidate that receives marketing approval are insufficient, DiamiR will not achieve profitability. Even
if DiamiR does achieve profitability, DiamiR may not be able to sustain or increase profitability.

<div align='center'>145</div>

Since inception, DiamiR has
raised over $9.7 million in grant funding from government agencies and disease foundations. On October 1, 2020, DiamiR announced
that it received two grants from the National Institutes of Health (NIH) in the total amount of approximately $3.86 million. The
National Institute on Aging (NIA) awarded DiamiR approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as
part of its Small Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration
with leading academic centers and continues to support development of CogniMIR, DiamiR’s lead diagnostic product
candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR
by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs
as biomarkers of Rett Syndrome.” As of August 31, 2025, funding available under these grants has been exhausted.

The consolidated financial
statements for the year ended May 31, 2025, that are included herein and the unaudited consolidated financial statement for the period
ended August 31, 2025, that are incorporated by reference into this prospectus, have been prepared assuming that DiamiR will continue
as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course
of business. Neither the audited consolidated financial statement nor the unaudited consolidated financial statements include any adjustments
that might be necessary if DiamiR is unable to continue as a going concern.

Recent Events

In August 2025, DiamiR
received a Clinical Laboratory Evaluation Program (